Alterations of liver function test in patients treated with antipsychotics

Abstract

The prevalence of alterations of liver function tests in patients treated with a wide range of antypsychotics is unknown. The aim of this study was to analyze the effects of antipsychotics on liver function tests in a population of schizophrenic outpatients. Concentrations of AST, ALT, GGT, alkaline phosphatase, albumin, and bilirubin were determined in 54 patients fitting DSM-IV criteria of schizophrenia, and the same number of sex- and age-matched healthy subjects. Assessments included the Clinical Global Impression (CGI) and the Positive and Negative Syndrome Scale (PANSS) in addition to treatment related variables. Transaminases concentrations were slightly elevated in study patients compared to healthy controls, but without statistical significance. Alkaline phosphatase showed higher values in schizophrenic patients. Albumin and bilirubin were lower in study patients. Liver function tests abnormalities were found in about 10% of schizophrenic patients treated with antipsychotics. Treatment with depot phenotiazines induces alteration in these tests more frequently than treatment with other antipsychotics. PANSS negative subscale scores directly correlated with alkaline phosphatase and inversely correlated with albumin. A substantial number of patients in treatment with antipsychotic drugs present alterations of liver function tests. Both pharmacological and clinical factors could be related with these alterations.

The Impact of Cannabis Use on the Dosage of Antipsychotic Drugs for Patients Admitted on the Psychiatric Ward at the University Hospital of the West Indies

“…This finding is consistent with documented studies, as these enzymes are reportedly high during the acute stages of psychosis (14)(15)(16)(17)(18)(19). Statistical results showed that this elevation was not significantly different between the dosing groups (CPZE1 and CPZE2).…”

Study of nonenzymatic antioxidants in schizophrenic patients

“…Reddy R et al reported significant decrease in bilirubin levels in first episode schizophrenics. 9 Our findings have fair correlation with the findings of Yao JK et al, Umadevi P and Murugan S, Teresa M et al 14,15,21 Yao JK et al also demonstrated significantly lower plasma bilirubin levels in chronic schizophrenic patients either during haloperidol treatment or in a drug-free condition compared with age-and sex-matched healthy volunteers.…”

Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes

“…Such studies could also provide information on important risk factors for CHD, including clinical indicators (e.g., cholesterol levels), obesity, and smoking status, which were not available in our health services encounter data. We also were not able to ascertain whether antipsychotic-induced elevated liver enzymes (Garcia-Unzueta et al, 2003) or other liver disorders such as hepatitis that affect many people with SMI (Essock et al, 2003) influenced the prescribing of statins in our study. Finally, although our findings suggest that a lack of guideline concordant care regarding use of cardioprotective medications may contribute, in part, to the increased cardiovascular morbidity and mortality observed in SMI patients, more work is required to elucidate the direct mechanisms leading to poor health outcomes in this population.…”